| Title |
Author |
Type |
Date |
Words |
| Russia's Colorectal Cancer Drug Market Projected to Grow to More Than $480 Million in 2016. |
|
|
May 30, 2012 |
585 |
| City man in cancer drug first. |
|
|
May 30, 2012 |
354 |
| CANCER PILL HOPE. |
|
|
May 29, 2012 |
101 |
| Research and Markets: Pharmacogenomics in Clinical Therapeutics: Comprehensive Overview for All Clinicians, Pharmacologists and Clinical Laboratory Professionals. |
|
|
May 29, 2012 |
355 |
| Anti-psychotic drug kills cancer stem cells without side-effects: study. |
|
|
May 27, 2012 |
392 |
| Minister rules out cancer drug fund. |
|
|
May 25, 2012 |
174 |
| Minister under fire over cancer drugs fund stance; GRIFFITHS SAYS THAT MOVE WOULD NOT BE IN PATIENTS' BEST INTERESTS. |
|
|
May 25, 2012 |
650 |
| Drug may 'tame' cancer cells. |
|
|
May 25, 2012 |
252 |
| Cancer drugs fund stance offers little comfort to those affected; Western Mail. |
|
|
May 25, 2012 |
450 |
| Minister says no to cancer drugs fund. |
|
|
May 25, 2012 |
372 |
| Research and Markets: Four-S Fortnightly PharmaHealth Track - Newsletter on Indian Healthcare Industry - Issue 5 - Cipla Makes Significant Price Cuts on 3 Cancer Drugs. |
|
|
May 25, 2012 |
374 |
| Blueprint Medicines Welcomes Fidelity Biosciences to Investor Syndicate. |
|
|
May 24, 2012 |
703 |
| MDLinx Survey: Ninety Percent of US Oncologists Report Crucial Cancer Drug Shortage. |
|
|
May 23, 2012 |
678 |
| 'Orphan' sleep drug could be new weapon to fight cancer. |
|
|
May 22, 2012 |
491 |
| New cancer fighting strategy discovered. |
|
|
May 22, 2012 |
655 |
| Over 90 Percent of Surveyed Hematologist-Oncologists in the U.S. are Aware that Takeda/Millennium's Subcutaneous Velcade is Approved for the Treatment of Myeloma. |
|
|
May 22, 2012 |
750 |
| Prodigy Generics and eVenus Announce the Launch of Oncology Injectable Irinotecan. |
|
|
May 22, 2012 |
320 |
| CEL-SCI Corporation Releases Letter to Shareholders. |
|
|
May 18, 2012 |
1843 |
| Research and Markets: Taxotere (Breast Cancer) - Analysis and Forecasts to 2020. |
|
Report |
May 18, 2012 |
417 |
| Active Biotech and Ipsen to Present Tasquinimod Phase II Overall Survival Data at the 2012 ASCO Annual Meeting. |
|
Conference news |
May 18, 2012 |
1344 |
| Research and Markets: Cytotoxic Therapies Market to 2017 - Launch of Next Generation Camptothecin Analogues Will Help Offset Revenue Loss due to Generic Erosion. |
|
|
May 18, 2012 |
403 |
| Research and Markets: Gemzar (Ovarian Cancer) - Analysis and Forecasts to 2020. |
|
Report |
May 18, 2012 |
422 |
| Spectrum Pharmaceuticals Commences Phase 2 Study of ZEVALIN[R] in Combination with the Redox Modulating Agent Motexafin Gadolinium (MGd). |
|
|
May 17, 2012 |
1392 |
| Dendreon Announces Presentation of PROVENGE Data at the 2012 American Society of Clinical Oncology Annual Meeting. |
|
|
May 16, 2012 |
2136 |
| Prostate cancer drug gets approval. |
|
|
May 16, 2012 |
279 |
| Genentech Will Report New Data on Important Progress for People with Advanced Cancers at ASCO 2012. |
|
|
May 16, 2012 |
3837 |
| Epizyme Announces Appointment of Eric Hedrick, M.D., as Chief Medical Officer. |
|
|
May 16, 2012 |
400 |
| Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019. |
|
Industry overview |
May 15, 2012 |
2232 |
| Cipla to cut prices of six anti- cancer medicines. |
|
|
May 11, 2012 |
323 |
| Postcode lottery warning after cancer drug refusal. |
|
|
May 11, 2012 |
192 |
| Research and Markets: Taxol (Breast Cancer) - Analysis and Forecasts to 2020. |
|
|
May 11, 2012 |
339 |
| Research and Markets: Tarceva (Pancreatic Cancer) - Analysis and Forecasts to 2020. |
|
|
May 11, 2012 |
320 |
| Research and Markets: Global Malignant Melanoma Drug Pipeline Capsule - 2012. |
|
|
May 11, 2012 |
403 |
| Research and Markets: Global Brain Cancer Drug Pipeline Capsule - 2012. |
|
|
May 11, 2012 |
402 |
| Research and Markets: Global Gastric Cancer Drug Pipeline Capsule - 2012. |
|
|
May 11, 2012 |
404 |
| For the Treatment of Advanced Melanoma, Oncologists Report that Yervoy and Zelboraf have Joined Temodar as the Leading Agents for First-line Therapy. |
|
Clinical report |
May 10, 2012 |
794 |
| Onconova Advances Oral Rigosertib to Phase II Clinical Trial in Myelodysplastic Syndromes. |
|
|
May 10, 2012 |
1043 |
| Commercializing Pancreatic Cancer Drugs: The Faster Route to Consider Your Options and Position of Others. |
|
|
May 10, 2012 |
5081 |
| Disappointment for Men With Advanced Prostate Cancer As Life-Extending Drug[1]Refused by NICE. |
|
|
May 10, 2012 |
816 |
| IBN's Droplet Array Sheds Light on Drug-Resistant Cancer Stem Cells. |
|
|
May 9, 2012 |
1002 |
| Research and Markets: Rising number of cancer cases making India potential market for anti-cancer drugs, finds Netscribes. |
|
|
May 8, 2012 |
404 |
| Oncology Expert George Demetri, M.D., Joins Blueprint Medicines as a Clinical Advisor. |
|
|
May 8, 2012 |
758 |
| In 2020, FOLFIRI Plus Ramucirumab Will Earn Decision Resources' Proprietary Clinical Gold-Standard Status for the Second-Line Treatment of Metastatic Colorectal Cancer. |
|
|
May 8, 2012 |
770 |
| Action needed on drug funding; Yousay IN YOUR OPINION... |
|
|
May 7, 2012 |
430 |
| Brain images questioned. |
Clauson, Bob |
Letter to the editor |
May 5, 2012 |
168 |
| Hopes for skin cancer drug deal; HEALTH. |
|
|
May 4, 2012 |
139 |
| Action needed on cancer drug funding; & COMMENT DEBATE YOUR LETTERS TO THE NATIONAL NEWSPAPER OF WALES. |
|
|
May 4, 2012 |
414 |
| Indian drug giant Cipla slashes cancer drug prices. |
|
|
May 4, 2012 |
539 |
| Potential to Revive Abandoned Cancer Drug by Nanoparticle Drug Delivery. |
|
|
May 3, 2012 |
338 |
| Exelixis Expands the Cabozantinib Development Program Through NCI-CTEP Collaboration. |
|
|
May 3, 2012 |
1492 |
| Teenager is giving back to RVI unit; Family's gratitude to cancer ward. |
|
|
May 2, 2012 |
414 |
| The International Myeloma Foundation Applauds Delaware and Virginia Legislatures for Passing Oral Drug Parity Bills. |
|
|
May 2, 2012 |
682 |
| ZIOPHARM Oncology Presents Preclinical Data at AACR Meeting. |
|
|
May 1, 2012 |
880 |
| ZIOPHARM Oncology Provides Update on PICASSO 3 Trial. |
|
|
May 1, 2012 |
753 |
| National Patient Advocate Foundation Praises Signing of the Delaware Cancer Treatment Access Act into Law. |
|
|
May 1, 2012 |
488 |
| CHF risk Is 5-Fold higher in trastuzumab users. |
Ault, Alicia |
|
May 1, 2012 |
570 |
| FDA warns of counterfeit anti-cancer drug Avastin [R]. |
Finkel, J. |
Brief article |
May 1, 2012 |
209 |
| Diclofenac sodium 3% gel for the management of actinic keratosis: 10+ years of cumulative evidence of efficacy and safety. |
Martin, George M.; Stockfleth, Eggert |
|
May 1, 2012 |
6596 |
| Psoriasis and its comorbidities. |
Onumah, Neh; Kircik, Leon H. |
Report |
May 1, 2012 |
5054 |
| Melanoma awareness explains rise in survival. |
Jancin, Bruce |
|
May 1, 2012 |
705 |
| Untapped resources can aid in early melanoma detection. |
Jancin, Bruce |
|
May 1, 2012 |
610 |
| After being diagnosed wrongly I had to fight for correct cancer drug; MUM-OF-TWO IN BATTLE FOR LIFE-SAVING MEDICATION. |
|
|
Apr 30, 2012 |
864 |
| Katie needs all the help she can get; WeSAY IN OUR OPINION. |
|
|
Apr 28, 2012 |
198 |
| Why Not Wales? campaign fights for new drugs. |
|
|
Apr 28, 2012 |
264 |
| 'You'll do whatever you can to save your life' Woman's fight for cancer drug. |
|
|
Apr 28, 2012 |
779 |
| Iran Produces Anti-Cancer Drug from Arsenic. |
|
|
Apr 28, 2012 |
213 |
| New oncology day unit at North Tyneside Hospital. |
|
|
Apr 27, 2012 |
556 |
| Fertility drugs double chances of leukaemia. |
|
|
Apr 24, 2012 |
214 |
| Significant Improvement in Disability Scores Observed in Multiple Sclerosis Patients Who Received LemtradaTM* (Alemtuzumab) Compared With Rebif[R] in Phase III Trial. |
|
|
Apr 24, 2012 |
2977 |
| German Federal Regulator Confirms Additional Benefit of Anti-cancer Agent Halaven(R) for Metastatic or Locally Advanced Breast Cancer. |
|
|
Apr 24, 2012 |
1005 |
| IBN Discovers Human Neural Stem Cells with Tumor Targeting Ability - A Promising Discovery for Breast Cancer Therapy. |
|
|
Apr 20, 2012 |
1041 |
| Elekta Announces First Patients Treated with Major Breakthrough in Cancer Therapy. |
|
|
Apr 19, 2012 |
621 |
| Celek Pharmaceuticals to Present Recent Progress on its Anticancer Drug Candidate, CEL-031, at National Cancer Institute Investor Forum. |
|
|
Apr 18, 2012 |
783 |
| Cancer drug dropped. |
|
|
Apr 18, 2012 |
106 |
| Nuvilex Announces Invitation to Showcase Innovative Therapy for Cancer Treatment at Oncology Meeting in Kyoto, Japan. |
|
|
Apr 18, 2012 |
452 |
| Merck and Endocyte Enter Exclusive Worldwide Agreement to Develop and Commercialize Phase III Cancer Candidate Vintafolide (EC145). |
|
|
Apr 16, 2012 |
1715 |
| UnitedHealthcare Report Recommends Adopting New Cancer Care Payment Model to Reward Physicians for Health Outcomes. |
|
Report |
Apr 16, 2012 |
1327 |
| Scalp melanoma has worse prognosis than other sites. |
Osterweil, Neil |
|
Apr 15, 2012 |
608 |
| Is marijuana medicinal? |
Abrams, Donald I.; Trafton, Jodie |
|
Apr 15, 2012 |
1506 |
| University of Kansas Researchers Win Co-Inventorship Dispute over Cancer Drug Formulation Patents. |
|
|
Apr 6, 2012 |
1053 |
| Eisai Enters into Partnership with PharmaSwiss for Halaven (Eribulin) Promotion and Distribution in Central and Eastern European Countries. |
|
|
Apr 5, 2012 |
364 |
| How cancer drug causes diabetic-like symptoms. |
|
|
Apr 4, 2012 |
305 |
| New batch of fake Avastin shipped from UK to US. |
|
|
Apr 4, 2012 |
335 |
| Docetaxel Dominates First-Line Metastatic Castrate-Resistant Prostate Cancer Treatment, But Total Patient Share of Zytiga and Jevtana Reach Nearly 50 Percent in the Second and Third-Line Settings According to Surveyed Physicians. |
|
Clinical report |
Apr 3, 2012 |
732 |
| Acceleron's ACE-041 Combined with a VEGF Inhibitor Shows Potent Activity in Preclinical Model of VEGF-Resistant Renal Cell Carcinoma. |
|
|
Apr 3, 2012 |
661 |
| Cancer Therapeutics' First Product Achieves Preclinical Proof of Concept. |
|
|
Apr 3, 2012 |
559 |
| China's Colorectal Cancer Drug Market Expected to Grow to More Than $400 Million in 2016. |
|
|
Apr 2, 2012 |
581 |
| Eisai and Minophagen Pharmaceutical Conclude License Agreement Concerning the Development and Commercialization of Cutaneous T-Cell Lymphoma Treatment Bexarotene in Asia, Oceania, the Middle East and Eastern Europe. |
|
|
Apr 2, 2012 |
506 |
| War on cancer. |
Moss, Ralph |
|
Apr 1, 2012 |
2170 |
| Physician's Cancer Chemotherapy Drug Manual 2012. |
|
|
Apr 1, 2012 |
146 |
| Lethal shortages. |
Faloon, William |
Cover story |
Apr 1, 2012 |
1355 |
| Pregnancies can survive some cancers, therapies. |
Sullivan, Michele G. |
|
Apr 1, 2012 |
2967 |
| Gene predicts response to esophagogastric cancer therapy. |
London, Susan |
|
Apr 1, 2012 |
696 |
| HONOUR FOR BRAVE DOUBLE CANCER BOY. |
|
|
Mar 30, 2012 |
337 |
| ImmunoGen, Inc. Announces Conference Call at 8:00 am ET March 30, 2012 to Discuss Today's Favorable Announcements about Trastuzumab Emtansine (T-DM1) and about IMGN901. |
|
|
Mar 30, 2012 |
287 |
| e-Therapeutics' Phase I Clinical Trials of Cancer Drug ETS2101 Approved by Regulators. |
|
|
Mar 29, 2012 |
300 |
| In 2015, Nanoparticle Paclitaxel in Combination with Carboplatin Will Earn Decision Resources' Proprietary Clinical Gold Standard Status for First-Line Advanced Squamous Non-Small-Cell Lung Cancer. |
|
|
Mar 28, 2012 |
710 |
| Research and Markets: Triple Analysis: Lymphoma, Pancreatic Cancer and Angiogenesis. |
|
|
Mar 28, 2012 |
467 |
| Research and Markets: Triple Analysis: Angiogenesis, Antibodies and Peptides. |
|
|
Mar 28, 2012 |
469 |
| Spectrum Announces Launch of New Patient-to-Patient Educational Campaign for ZEVALIN[R] on ZEVALIN.com. |
|
|
Mar 27, 2012 |
1159 |
| Foundation Medicine, Cambridge, MA, Joins WIN Consortium (Paris) and Becomes Member of the Worldwide Innovative Networking in Personalized Cancer Medicine. |
|
|
Mar 27, 2012 |
646 |
| Research and Markets: Global Breast Cancer Drug Pipeline Capsule - 2012. |
|
|
Mar 27, 2012 |
411 |
| Study Establishes Safety and Clinical Benefit of SIR-Spheres[R] microspheres in Treating Metastatic Liver Tumors in Patients who Failed Systemic Chemotherapy. |
|
Clinical report |
Mar 27, 2012 |
615 |
| Clovis Oncology Completes Enrollment in Pivotal LEAP Trial of CO-101 versus Gemcitabine in Metastatic Pancreatic Cancer. |
|
|
Mar 26, 2012 |
1361 |
| Rising Number of Cancer Cases Making India Potential Market for Anti-Cancer Drugs, Finds Netscribes. |
|
|
Mar 21, 2012 |
334 |
| I fear I won't live to see birth of my grandchild; Cancer patient told: chance of if he vital drug... lived in England. |
|
|
Mar 20, 2012 |
650 |
| Gene variant in East Asians could explain resistance to cancer drugs. |
|
|
Mar 19, 2012 |
712 |
| 'Wonderpill' that can keep skin cancer patients alive for longer on sale. |
|
|
Mar 15, 2012 |
390 |
| Cancer drug blow. |
|
|
Mar 13, 2012 |
102 |
| A cheap drug for cancer in India soon. |
|
|
Mar 13, 2012 |
370 |
| Antidepressant 'could be promising cancer treatment drug'. |
|
|
Mar 12, 2012 |
470 |
| Fake Avastin shows very little protects drug supply. |
|
|
Mar 12, 2012 |
1346 |
| Cancer drug shows promise as treatment for Alzheimer's: in mice, medication clears plaque-forming protein. |
Sanders, Laura |
|
Mar 10, 2012 |
729 |
| Cancer drug helps flush hidden HIV virus. |
|
|
Mar 9, 2012 |
376 |
| 'Gaseous' aspirin could be potent anti-cancer drug. |
|
|
Mar 8, 2012 |
266 |
| Eisai Inc. Receives Complete Response Letter from U.S. Food and Drug Administration for DACOGEN[R] (decitabine) for injection sNDA in Acute Myeloid Leukemia. |
|
|
Mar 7, 2012 |
932 |
| Eisai Inc. Receives Complete Response Letter from the U.S. Food and Drug Administration for Dacogen[R] (decitabine) for Injection sNDA in Acute Myeloid Leukemia. |
|
|
Mar 7, 2012 |
1164 |
| WIN2012 Symposium on Personalized Cancer Medicine Receives Endorsements from ASCO, ESMO, UICC and INCa. |
|
|
Mar 7, 2012 |
455 |
| Research and Markets: The Global Cancer Drug Market to Grow At A CAGR Of 12.6 Percent over the Period 2010-2014. |
|
|
Mar 6, 2012 |
378 |
| President Inaugurates 40 Development Projects in Northern Iran. |
|
|
Mar 5, 2012 |
212 |
| Research and Markets: Market and Product Forecasts: Targeted Cancer Therapies - Trend towards Personalized Medicine Will Lead to Market Fragmentation. |
|
|
Mar 5, 2012 |
348 |
| APP Pharmaceuticals Announces Expanded Supply of Methotrexate Injection, USP. |
|
|
Mar 3, 2012 |
953 |
| "Cancer Drug Market Will Reach $75 Billion in 2012" Visiongain Report Predicts. |
|
|
Mar 2, 2012 |
502 |
| Cancer Drug Market To Reach $75 Billion in 2012. |
|
|
Mar 1, 2012 |
712 |
| Phase 3 trial of PV-10 for metastatic melanoma. |
|
Brief article |
Mar 1, 2012 |
113 |
| Nuvilex Reveals Goldman Small Cap Research Cites Groundbreaking Cancer Therapy in Updating Buy Recommendation. |
|
|
Feb 29, 2012 |
822 |
| Tau Therapeutics IND Accepted by FDA for Novel Cancer Drug. |
|
|
Feb 28, 2012 |
474 |
| Research and Markets: Breast Cancer Drug Pipeline Update 2012 - Currently There Are 331 Companies plus Partners Developing 450 Drugs Targeting Breast Cancer in Development. |
|
|
Feb 28, 2012 |
401 |
| Research and Markets: Leukemia Drug Pipeline Update 2012 Contains 321 Leukemia Drugs in Development, Which Have a Total of 474 Developmental Projects in Cancer. |
|
|
Feb 28, 2012 |
371 |
| Research and Markets: Lung Cancer Drug Pipeline Update 2012 Contains 426 Lung Cancer Drugs in Development, Which Have a Total of 507 Developmental Projects in Cancer. |
|
|
Feb 28, 2012 |
434 |
| Research and Markets: Today 212 Companies Plus Partners Are Developing 286 Drugs Targeting Ovarian Cancer Says 2012 Report. |
|
|
Feb 28, 2012 |
413 |
| Compugen Presents Prediction Based Discovery Strategy at "Targets and Strategies for Drug Discovery" Conference. |
|
Conference news |
Feb 27, 2012 |
1268 |
| Targeted Cancer Drugs Market Analysed by Espicom in New Topical Report Now Available at MarketPublishers.com. |
|
|
Feb 27, 2012 |
514 |
| Targeted drug extends survival of leukemia patients. |
|
|
Feb 27, 2012 |
316 |
| Drugs are delayed 'to save cash'. |
|
|
Feb 26, 2012 |
103 |
| New cancer drugs 'axed' to save cash. |
|
|
Feb 26, 2012 |
148 |
| Research and Markets: Targeted Oncology. |
|
|
Feb 24, 2012 |
305 |
| New skin cancer drug 'almost doubles survival'. |
|
|
Feb 23, 2012 |
514 |
| Egyptian firm in fake Avastin scam proves elusive. |
|
|
Feb 22, 2012 |
490 |
| Egyptian firm in fake Avastin scam proves elusive. |
|
|
Feb 22, 2012 |
501 |
| APP Pharmaceuticals Announces Approval of Preservative-Free Methotrexate Injection, USP. |
|
|
Feb 22, 2012 |
763 |
| Research and Markets: Targeted Cancer Drugs The Launch Landscape to 2018. |
|
|
Feb 21, 2012 |
547 |
| The way patients apply for drugs funding to be reviewed; TRANSPARENCY OF HEALTH BOARD DECISIONS QUESTIONED. |
|
|
Feb 20, 2012 |
522 |
| Men can have breakthrough cancer drug. |
|
|
Feb 20, 2012 |
111 |
| Common malaria drug can enhance anti-cancer activity of chemotherapy. |
|
|
Feb 20, 2012 |
516 |
| Video games provide new targets for cancer drugs. |
|
|
Feb 19, 2012 |
375 |
| Iran to Produce New Anti-Cancer Drug Soon. |
|
|
Feb 19, 2012 |
336 |
| ImmunoCellular Therapeutics To Present at Targeting Stem Cells Symposium during 19th Annual Molecular Medicine Tri-Conference. |
|
|
Feb 17, 2012 |
475 |
| New Drug Target Found for Lung Cancer. |
|
|
Feb 17, 2012 |
527 |
| AstraZeneca Announces First Direct-to-Patient Program Offering the Brand ARIMIDEX[R] (anastrozole) Tablets to Patients for Only $40 Per Month. |
|
|
Feb 16, 2012 |
1039 |
| Eurycomanone suppresses expression of lung cancer cell tumor markers, prohibition, annexin 1 and endoplasmic reticulum protein 28. |
Wong, Pooi-Fong; Cheong, Wei-Fun; Shub, Meng-Hooi; Teh, Chin-Hoe; Chan, Kit-Lam; AbuBakarb, Sazaly |
Report |
Feb 15, 2012 |
5988 |
| Methotrexate toxicity countered. |
|
|
Feb 15, 2012 |
201 |
| Iran to Present New Anti-Cancer Nanodrug to Market Soon. |
|
|
Feb 15, 2012 |
336 |
| Launch of New Agents with Niche Roles Will Contribute to Drug Market Growth in the Treatment of Non-Muscle-Invasive Bladder Cancer. |
|
|
Feb 14, 2012 |
714 |
| Arno Therapeutics Announces Exclusive Licensing Agreement with Invivis Pharmaceuticals to Develop Cancer Drug. |
|
|
Feb 14, 2012 |
647 |
| Tiltan Pharma Commences Phase 2 Clinical Study of Anti-Angiogenic Treatment for Pancreatic Cancer. |
|
|
Feb 13, 2012 |
746 |
| SCIENTISTS have discovered a potential [...]. |
|
|
Feb 13, 2012 |
247 |
| Blocking DNA repair enzyme could eventually lead to cancer therapy. |
|
|
Feb 11, 2012 |
537 |
| Cancer drug quickly reverses Alzheimer's symptoms in mice. |
|
|
Feb 10, 2012 |
473 |
| GOVERNMENT 'DOES NOT SEE NEED FOR A SEPARATE CANCER DRUG FUND IN WALES'. |
|
|
Feb 6, 2012 |
398 |
| Maryland's Cancer Care Community, Patient Advocates Urge State Legislature to Create Parity in Coverage for Preferred Cancer Drugs. |
|
|
Feb 6, 2012 |
585 |
| Argos Therapeutics Announces New Data Demonstrating Prolonged Overall Survival in a Phase 2 Study of its Arcelis[logical not]" Immunotherapy AGS-003 in Combination with Sunitinib in Patients with Metastatic Renal Cell Carcinoma (mRCC). |
|
Clinical report |
Feb 4, 2012 |
711 |
| Buyout Offer for Micromet Triggers Shareholder-Claim Investigation by Goldfarb LLP Securities Attorneys. |
|
|
Feb 3, 2012 |
307 |
| Decision to bar funding for cancer drug 'a blow'. |
|
|
Feb 2, 2012 |
264 |
| Alithiasic cholecystitis treated by percutaneous cholecystostomy in a patient with severe septic shock and neutropenia. |
Simion, N. |
Case study |
Feb 1, 2012 |
919 |
| Bleomycin toxicity post injection into craniopharyngioma. |
Norval, Ivan L.; Tynan, Jennifer R.; Frangou, Evan M. |
Clinical report |
Feb 1, 2012 |
1000 |
| Ustekinumab: a review in the treatment of plaque psoriasis and psoriatic arthritis. |
Zaghi, Daniel; Krueger, Gerald G.; Duffin, Kristina Callis |
Report |
Feb 1, 2012 |
6432 |
| Paclitaxel-associated subungual pyogenic granuloma: report in a patient with breast cancer receiving Paclitaxel and review of drug-induced pyogenic granulomas adjacent and beneath the nail. |
Paul, Laura J.; Cohen, Philip R. |
Clinical report |
Feb 1, 2012 |
3364 |
| Cancer care No longer immune to cost cutting. |
Jancin, Bruce |
|
Feb 1, 2012 |
1401 |
| Argos Therapeutic Arcelis[superscript two]"O Immunotherapy AGS-003 in Combination With Sunitinib Shows Statistically Significant Correlation of Immune System Response to Overall Survival in Phase 2 Study in Patients with Advanced Renal Cell Carcinoma (RCC). |
|
|
Jan 31, 2012 |
757 |
| Inherited Risk Factors for Childhood Leukemia are More Common in Hispanic Patients. |
|
|
Jan 30, 2012 |
1450 |
| Iran Unveils 6 New Home-Made Drugs. |
|
|
Jan 29, 2012 |
325 |
| Drug activates dormant gene: chemotherapy agent may treat Angelman syndrome. |
Saey, Tina Hesman |
|
Jan 28, 2012 |
344 |
| AFTER CHEMO LISA FEARED SHE'D NEVER HAVE KIDS - NOW SHE'S FIVE MONTHS PREGNANT; Mum-to-be looking forward to appearance on the catwalk after her five-year cancer battle. |
|
|
Jan 21, 2012 |
792 |
| New set of nanoparticles 'may accurately deliver cancer drugs to tumours'. |
|
|
Jan 20, 2012 |
481 |
| Ceptaris Therapeutics Receives EMA Orphan Drug Designation for Proprietary Mechlorethamine Gel. |
|
|
Jan 18, 2012 |
329 |
| Simcyp Develops Virtual Laboratory Mouse for Use in Cancer and Toxicology Research. |
|
|
Jan 18, 2012 |
455 |
| Niiki Pharma Announces the Completion of Phase I Dose Escalation for First-in-Man Anti-Cancer Agent NKP-1339. |
|
|
Jan 17, 2012 |
544 |
| Research and Markets: Oncology Market Access in India - The Commercial Potential is High, but Many Challenges Remain. |
|
|
Jan 17, 2012 |
417 |
| JPT Peptide Technologies, IUCT and LEITAT Announce Collaboration on the Development of Novel Biofocused Anticancer Therapies (NOBITAN). |
|
|
Jan 17, 2012 |
585 |
| Research and Markets: Global Bladder Cancer Drug Pipeline Capsule 2012. |
|
|
Jan 17, 2012 |
405 |
| 'Step in the right direction' for drugs treatment. |
|
|
Jan 16, 2012 |
638 |
| EXPERTS who have discovered new [...]. |
|
|
Jan 16, 2012 |
252 |
| Despite No Current Approval of Janssen's Zytiga in Asymptomatic/Minimally Symptomatic MCRPC, 31% of Surveyed Physicians Report Decreased Use of Dendreon's Provenge Because Zytiga is Available for Later Lines of Treatment. |
|
|
Jan 16, 2012 |
550 |
| Iran to Unveil 6 New Home-Made Anti-Cancer Drugs. |
|
|
Jan 15, 2012 |
340 |
| Research and Markets: Non-small Cell Lung Cancer Drug Market in South Korea: - Adenocarcinoma, Squamous cell carcinoma and Large cell carcinoma. |
|
|
Jan 13, 2012 |
410 |
| New Study Points to Relapse of Leukemia with Chemotherapy. |
|
Report |
Jan 13, 2012 |
1061 |
| Research and Markets: Gleevec - Analysis and Forecasts from 2013 to 2020. |
|
|
Jan 12, 2012 |
386 |
| Research and Markets: Global Cervical Cancer Drug Pipeline Capsule - 2012 Provides Information on Pipeline Molecules by Company and Mechanism of Action across the Different Stages of R&D. |
|
|
Jan 11, 2012 |
404 |
| FORMA Therapeutics Announces an Exclusive Cancer Drug Discovery Alliance Focused on Tumor Metabolism with Janssen Biotech, Inc. |
|
|
Jan 10, 2012 |
391 |
| NantWorks to Invest $85.5 Million in New Vigo County Facility. |
|
|
Jan 10, 2012 |
638 |
| Research and Markets: Global Lung Cancer Drug Pipeline Capsule - 2012 Report Helps Executives to Keep Abreast of Their Competitors and Understand Their Pipeline Molecules. |
|
|
Jan 10, 2012 |
404 |
| Research and Markets: Triple Analysis: Lymphoma, Apoptosis and Peptides. |
|
|
Jan 6, 2012 |
592 |
| Goff Hill Ltd. Announces the Cure for Cancer and Viral Diseases. |
|
|
Jan 5, 2012 |
487 |
| Viamet Pharmaceuticals Initiates Phase 1/2 Clinical Trial of Novel Prostate Cancer Therapy, VT-464. |
|
|
Jan 4, 2012 |
555 |
| Bio-Path Holdings to Present at the Biotech Showcase[TM] 2012 Conference. |
|
Conference news |
Jan 4, 2012 |
440 |
| Nanotechnology breakthrough for cancer patients. |
|
|
Jan 4, 2012 |
295 |
| AVEO and Astellas Announce Tivozanib Successfully Demonstrated Progression-Free Survival Superiority over Sorafenib in Patients with Advanced Renal Cell Cancer in Phase 3 TIVO-1 Trial. |
|
|
Jan 3, 2012 |
1673 |
| Patients need confidence in system giving access to vital cancer druigs; Western Mail. |
|
|
Jan 2, 2012 |
432 |
| Cancer patients face drugs 'double blow'. |
|
|
Jan 2, 2012 |
632 |
| Health bosses plea for donors to help sickest patients. |
|
|
Jan 2, 2012 |
376 |
| Synthesis and evaluation of novel phosphasugar anticancer agents. |
Yamaoka, Mayumi; Yamashita, Mitsuji; Yamada, Manabu; Fujie, Michio; Kiyofuji, Keita; Ozaki, Nobuhisa |
Report |
Jan 1, 2012 |
5818 |
| Beta-blockers appear to prevent cardiotoxic effects of trastuzumab. |
Jancin, Bruce |
Clinical report |
Jan 1, 2012 |
451 |
| Childhood malignancy and cardiotoxicity of anthracyclines. |
Sorkhabi, Rouhangiz; Rastkar, Bahman; Mohseni-Tavakooli, Said; Faranoush, Mohammad |
Report |
Jan 1, 2012 |
2790 |
| Molecular interactions between anticancer drugs and iodinated contrast media: an in vitro spectroscopic study. |
Ishii, Ryoichi; Mori, Hiromu; Matsumura, Kenji; Hongo, Norio; Kiyosue, Hiro; Matsumoto, Shunro; Yosh |
Report |
Jan 1, 2012 |
5248 |
| A cholesterol and actinide dependent shadow biosphere of archaea and viroids in neoplastic disorders. |
Kurup A., Ravikumar; Kurup, Parameswara Achutha |
Report |
Dec 31, 2011 |
4241 |
| Emergent Initiates Phase 2 Study of TRU-016 in Combination with Bendamustine in Patients with Relapsed Chronic Lymphocytic Leukemia. |
|
|
Dec 28, 2011 |
682 |
| Kyodo news summary -8-. |
|
|
Dec 27, 2011 |
446 |
| NCC Announces its Childhood Cancer Research Coalition Program Grant Recipients. |
|
|
Dec 26, 2011 |
519 |
| pounds 2m grant for research to battle cancer. |
|
|
Dec 23, 2011 |
192 |
| Celek Pharmaceuticals Receives National Cancer Institute Award to Develop CEL-031 for the Treatment of Bladder Cancer. |
|
|
Dec 22, 2011 |
788 |
| Soon, light to measure cancer cells' response to treatment. |
|
|
Dec 21, 2011 |
382 |
| Research and Markets: Provenge Fails to Live up to Dendreon's Expectations. |
|
|
Dec 19, 2011 |
313 |
| Saladax Biomedical, Inc. Expands Distribution of My5-FU in Europe. |
|
|
Dec 16, 2011 |
671 |
| Novocure Adds Three Senior Oncology Executives to its Global Management Team. |
|
|
Dec 16, 2011 |
1026 |
| Eisai Announces Canadian Approval of its Anticancer Agent Halaven. |
|
|
Dec 15, 2011 |
494 |
| Piperine, a piperidine alkaloid from Piper nigrum re-sensitizes P-gp, MRP1 and BCRP dependent multidrug resistant cancer cells. |
Li, Sen; Lei, Yu; Jia, Yingjie; Li, Na; Wink, Michael; Ma, Yonggang |
Report |
Dec 15, 2011 |
3529 |
| Russia's Non-Small-Cell Lung Cancer Drug Market Will Grow to $163 Million in 2015. |
|
|
Dec 14, 2011 |
493 |
| Bio-Path Holdings' Initial Phase I Data in Leukemia Clinical Trial Demonstrates That Its Neutral Lipid Delivery Technology Antisense Drug BP-100-1.01 (Liposomal Grb-2) is Well Tolerated with Activity Seen at Low Starting Dose. |
|
|
Dec 13, 2011 |
1107 |
| 'Trial' drug associated with 70pc response rate in chronic lymphocytic leukaemia. |
|
|
Dec 12, 2011 |
354 |
| Breast cancer treatment may impair survivors' mental abilities. |
|
|
Dec 12, 2011 |
314 |
| CANCER patients who suffer severe [...]. |
|
|
Dec 12, 2011 |
176 |
| TetraLogic Pharmaceuticals Announces Oral Presentation on Smac Mimetic TL32711 at American Society of Hematology (ASH) Annual Meeting. |
|
|
Dec 11, 2011 |
592 |
| Biotech firm wins pounds 450k funding boost; ADC BIOTECHNOLOGY DEVELOPS CANCER DRUGS. |
|
|
Dec 10, 2011 |
497 |
| Evidence Base for VELCADE Builds as new Data is Presented at 53rd American Society of Hematology Annual Meeting. |
|
|
Dec 9, 2011 |
1217 |
| Research and Markets: Triple Analysis: Leukemia, Lung Cancer and Pancreatic Cancer. |
|
|
Dec 9, 2011 |
387 |
| Research and Markets: Triple Analysis: Leukemia, Lung Cancer and Prostate Cancer. |
|
|
Dec 9, 2011 |
387 |
| Research and Markets: Triple Analysis: Leukemia, Lung Cancer and Melanoma. |
|
|
Dec 9, 2011 |
385 |
| New cancer drugs hope; Treatment to help extend patients' lives. |
|
|
Dec 8, 2011 |
427 |
| Research and Markets: Triple Analysis: Leukemia, Lymphoma and Melanoma. |
|
|
Dec 8, 2011 |
383 |
| Research and Markets: Triple Analysis: Lung Cancer, Pancreatic Cancer and Prostate Cancer. |
|
|
Dec 8, 2011 |
389 |
| Research and Markets: Triple Analysis: Colorectal Cancer, Prostate Cancer and Peptides. |
|
|
Dec 8, 2011 |
394 |
| The Renal Cell Carcinoma Drug Market Will Experience Robust 3.7 Percent Annual Growth from 2010 to 2020. |
|
|
Dec 8, 2011 |
807 |
| Janssen Biotech, Inc. Announces Collaborative Development and Worldwide License Agreement for Investigational Anti-Cancer Drug, PCI-32765. |
|
|
Dec 8, 2011 |
727 |
| Research and Markets: Triple Analysis: Leukemia, Lymphoma and Prostate Cancer. |
|
|
Dec 7, 2011 |
385 |
| CEL- SCI Corporation Updates Phase III Clinical Activities for Investigational Cancer Therapy Multikine (Leukocyte Interleukin, Injection). |
|
|
Dec 7, 2011 |
843 |
| Decision Resources to Release Bladder Cancer Drug Market Forecast Through 2020. |
|
Industry overview |
Dec 7, 2011 |
423 |
| Global Cancer Therapies Industry. |
|
Industry overview |
Dec 7, 2011 |
373 |
| ZIOPHARM Granted European Patent Allowance for Palifosfamide. |
|
|
Dec 7, 2011 |
1100 |
| Research and Markets: Triple Analysis: Colorectal Cancer, Lymphoma and Peptides. |
|
|
Dec 7, 2011 |
534 |
| Research and Markets: Triple Analysis: Leukemia, Lymphoma and Peptides. |
|
|
Dec 7, 2011 |
550 |
| Research and Markets: Triple Analysis: Leukemia, Lymphoma and Pancreatic Cancer. |
|
|
Dec 7, 2011 |
385 |
| Research and Markets: Triple Analysis: Leukemia, Prostate Cancer and Peptides. |
|
|
Dec 6, 2011 |
392 |
| Research and Markets: Triple Analysis: Lung Cancer, Lymphoma and Melanoma. |
|
|
Dec 6, 2011 |
385 |
| Research and Markets: Triple Analysis: Breast Cancer, Pancreatic Cancer and Peptides. |
|
|
Dec 6, 2011 |
543 |
| Research and Markets: Triple Analysis: Colorectal Cancer, Lung Cancer and Peptides. |
|
|
Dec 6, 2011 |
559 |
| Research and Markets: Pancreatic Cancer, Antibodies and Peptides: a Triple Analysis from Bioseeker. |
|
|
Dec 6, 2011 |
395 |
| Research and Markets: Triple Analysis: Breast Cancer, Lung Cancer and Protein Kinase Inhibitors. |
|
|
Dec 5, 2011 |
399 |
| Research and Markets: Triple Analysis: Breast Cancer, Lymphoma and Prostate Cancer. |
|
|
Dec 5, 2011 |
394 |
| Despite the Generic Erosion of Key Agents, the Non-Small-Cell Lung Cancer Drug Market Will Increase 2.5 Percent Annually Between 2010 and 2020. |
|
|
Dec 5, 2011 |
872 |
| Research and Markets: Triple Analysis: Breast Cancer, Lung Cancer and Protein Kinase Inhibitors. |
|
|
Dec 5, 2011 |
379 |
| New drug may be 'irresistible' to cancer cells; WELSH SCIENTISTS' BREAKTHROUGH. |
|
|
Dec 1, 2011 |
576 |
| A NEW CANCER DRUG; Scientists stop treatments becoming resistant to disease. |
|
|
Dec 1, 2011 |
584 |
| MacroGenics and Servier Enter Development and Commercialization Agreement for Novel Anti-Cancer Drug. |
|
|
Dec 1, 2011 |
1217 |
| H3 Biomedicine Inc. Unveils New Headquarters and Laboratories in Cambridge, Massachusetts. |
|
|
Dec 1, 2011 |
944 |
| War on cancer. |
Moss, Ralph |
|
Dec 1, 2011 |
2436 |
| Evolving research methods in cytology it's the era of laser scanning imaging-based technology. |
Gaisford, Wendy |
Report |
Dec 1, 2011 |
1795 |
| Erythema multiforme-like drug reaction to sorafenib. |
Lewin, Jesse; Farley-Loftus, Rachel; Pomeranz, Miriam Keltz |
Clinical report |
Dec 1, 2011 |
964 |
| Second malignant tumors in childhood cancer survivors/ Cocukluk cagi kanser sag kalanlarinda ikincil kanserler. |
Kebudi, Rejin; Ozdemir, Gul Nihal |
Report |
Dec 1, 2011 |
3416 |
| Embryoprotein TWIST distribution in breast cancer cells MDA-MB-231 treated with 5-Fluorouracil and malnutrition. |
Escobar-Cabrera, Jesica; Rodriguez-Torres, Angelina; Berumen-Segura, Laura; Alcocer, Guadalupe Garci |
Report |
Dec 1, 2011 |
2525 |
| WIN Consortium Announces the WIN Symposium 2012 in Personalized Cancer Medicine, Paris, June 28-29, 2012. |
|
|
Nov 30, 2011 |
405 |
| Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Combination Study of MM-121 and Multiple Anticancer Therapies in Patients with Advanced Solid Tumors. |
|
|
Nov 30, 2011 |
279 |
| The Gastric Cancer Drug Market Will Experience Robust Growth, Increasing From Just Under $800 Million in 2010 to Nearly $1.4 Billion in 2020. |
|
|
Nov 29, 2011 |
938 |
| Exelixis Signs CRADA With National Cancer Institute to Expand Development Plan of Cabozantinib. |
|
|
Nov 28, 2011 |
1155 |
| Research and Markets: Triple Analysis: Leukemia, Prostate Cancer and Antibodies. |
|
|
Nov 28, 2011 |
337 |
| Research and Markets: Triple Analysis: Leukemia, Lymphoma and Antibodies. |
|
|
Nov 28, 2011 |
338 |
| TEENAGE patients suffering from one [...]. |
|
|
Nov 28, 2011 |
232 |
| Updated: UT Cancer Institute Focuses on Effective Drug Research. |
|
|
Nov 28, 2011 |
838 |
| HOW THE HEEL DID THEY GET SO HUGE? TOE-MENDOUS TEEN STUNS MEDICS. |
|
|
Nov 27, 2011 |
466 |
| Research and Markets: Triple Analysis: Breast Cancer, Melanoma and Peptides - This Report Will Be an Important Part of Creating and Implementing a Market Development Plan for Cancer Drugs. |
|
|
Nov 25, 2011 |
512 |
| Research and Markets: Triple Analysis: Leukemia, Protein Kinase Inhibitors and Peptides. |
|
|
Nov 25, 2011 |
451 |
| Research and Markets: Triple Analysis: Melanoma, Pancreatic Cancer and Peptides. |
|
|
Nov 25, 2011 |
432 |
| Research and Markets: Triple Analysis: Lung Cancer, Melanoma and Antibodies. |
|
|
Nov 25, 2011 |
445 |
| Research and Markets: Triple Analysis: Lymphoma, Pancreatic Cancer and Antibodies. |
|
|
Nov 25, 2011 |
467 |
| Research and Markets: Triple Analysis: Breast Cancer, Lymphoma and Apoptosis - 2011 Edition. |
|
|
Nov 25, 2011 |
346 |
| Research and Markets: Triple Analysis: Breast Cancer, Lung Cancer and Apoptosis - 2011 Provides Systems, Analytical and Strategic Support both Internally To PPP and To Stakeholders. |
|
|
Nov 25, 2011 |
352 |
| Research and Markets: Triple Analysis: Leukemia, Lung Cancer and Peptides - 2011 Will Be an Important Part of Creating and Implementing a Market Development Plan for Cancer Drugs. |
|
|
Nov 25, 2011 |
344 |
| NHS is for saving lives, not money; RECORD Letters Comment OF THE DAY. |
|
Letter to the editor |
Nov 24, 2011 |
131 |
| Cancer medicine component could prevent heart attacks. |
|
|
Nov 24, 2011 |
370 |
| Research and Markets: Triple Analysis: Leukemia, Antibodies and Peptides. |
|
|
Nov 24, 2011 |
443 |
| Research and Markets: Apoptosis, Antibodies and Peptides: Cancer Drug Development Strategies. |
|
|
Nov 24, 2011 |
538 |
| Bat Plant shows cancer-fighting potential. |
|
|
Nov 23, 2011 |
313 |
| Research and Markets: Triple Analysis: Leukemia, Lung Cancer and Antibodies. |
|
|
Nov 23, 2011 |
473 |
| Research and Markets: Triple Analysis: Colorectal Cancer, Apoptosis and Antibodies. |
|
|
Nov 22, 2011 |
476 |
| Research and Markets: Triple Analysis: Colorectal Cancer, Angiogenesis and Antibodies. |
|
|
Nov 22, 2011 |
476 |
| Mum's fury over cancer drugs snub; HEALTH. |
|
|
Nov 21, 2011 |
159 |
| Latest drugs scarce in 'low-spend' Wales NHS; Latest drugs scarcer onWales NHS than they are in England. |
|
|
Nov 21, 2011 |
676 |
| Research and Markets: Triple Analysis: Colorectal Cancer, Pancreatic Cancer and Antibodies. |
|
|
Nov 21, 2011 |
471 |
| FDA Approves the Removal of the Bioscan Requirement for ZEVALIN[R] Treatment. |
|
|
Nov 21, 2011 |
1602 |
| Research and Markets: Triple Analysis: Colorectal Cancer, Prostate Cancer and Antibodies. |
|
|
Nov 21, 2011 |
468 |
| Research and Markets: Triple Analysis: Breast Cancer, Lymphoma and Antibodies. |
|
|
Nov 18, 2011 |
470 |
| Research and Markets: Triple Analysis: Leukemia, Apoptosis and Antibodies. |
|
|
Nov 18, 2011 |
574 |
| Research and Markets: Triple Analysis: Lung Cancer, Apoptosis and Antibodies. |
|
|
Nov 18, 2011 |
577 |
| Research and Markets: Lung Cancer Drugs Market in G7 Countries (2005 - 2020) - This report studies the market from 2005 to 2020 covering eleven major drugs for lung cancer treatment. |
|
|
Nov 17, 2011 |
590 |
| Research and Markets: Triple Analysis: Breast Cancer, Melanoma and Antibodies. |
|
|
Nov 17, 2011 |
575 |
| Research and Markets: Triple Analysis: Leukemia, Protein Kinase Inhibitors and Antibodies. |
|
|
Nov 17, 2011 |
535 |
| Research and Markets: Triple Analysis: Prostate Cancer, Antibodies and Peptides. |
|
|
Nov 17, 2011 |
380 |
| Polaris group to build factory in Taiwan to produce anti-cancer drug. |
Liang, Quincy |
|
Nov 17, 2011 |
316 |
| Although Herceptin's Dominance of the Breast Cancer Drug Market in Europe is Threatened by Potential Biosimilar Erosion, the Uptake of Biosimilars May Be Hampered by European Oncologists' and Payers' Perceptions of Biosimilars. |
|
|
Nov 16, 2011 |
619 |
| Research and Markets: Triple Analysis: Colorectal Cancer, Lung Cancer and Antibodies. |
|
|
Nov 16, 2011 |
593 |
